Postpartum Reclassification of Glycemic Status in Women with Gestational Diabetes Mellitus and Associated Risk Factors

Reclassificação pós-parto do estado glicêmico em mulheres com diabetes mellitus gestacional e fatores de risco associados

Jacy Maria Alves1  Aline Stollmeier2  Isabelle Gasparetto Leite2  Camilla Gallo Pilger2  Josiane Cristine Melchiorett Detsch1  Rosana Bento Radominski1  Rosângela Roginski Rêa1

1 Endocrinology and Metabolism Service, Hospital de Clínicas, Universidade Federal do Paraná (UFPR), Curitiba, PR, Brazil
2 Medical School, Universidade Federal do Paraná, Curitiba, PR, Brazil

Address for correspondence  Jacy Maria Alves, MD, MSc, Hospital de Clínicas, Universidade Federal do Paraná, Avenida Agostinho Leão Junior, 285, 80030-110, Curitiba, PR, Brasil (e-mail: jacy.alves@yahoo.com.br).

Abstract

Objective  The aims of the study were to evaluate, after pregnancy, the glycemic status of women with history of gestational diabetes mellitus (GDM) and to identify clinical variables associated with the development of type 2 diabetes mellitus (T2DM), impaired fasting glucose (IFG), and impaired glucose tolerance (IGT).

Methods  Retrospective cohort of 279 women with GDM who were reevaluated with an oral glucose tolerance test (OGTT) after pregnancy. Characteristics of the index pregnancy were analyzed as risk factors for the future development of prediabetes (IFG or IGT), and T2DM. Results: T2DM was diagnosed in 34 (12.2%) patients, IFG in 58 (20.8%), and IGT in 35 (12.5%). Women with postpartum T2DM showed more frequently a family history of T2DM, higher pre-pregnancy body mass index (BMI), lower gestational age, higher fasting and 2-hour plasma glucose levels on the OGTT at the diagnosis of GDM, higher levels of hemoglobin A1c, and a more frequent insulin requirement during pregnancy. Paternal history of T2DM (odds ratio [OR] = 5.67; 95% confidence interval [95%CI] = 1.64–19.59; p = 0.006), first trimester fasting glucose value (OR = 1.07; 95%CI = 1.03–1.11; p = 0.001), and insulin treatment during pregnancy (OR = 15.92; 95%CI = 5.54–45.71; p < 0.001) were significant independent risk factors for the development of T2DM.

Conclusion  A high rate of abnormal glucose tolerance was found in women with previous GDM. Family history of T2DM, higher pre-pregnancy BMI, early onset of GDM, higher glucose levels, and insulin requirement during pregnancy were important risk factors for the early identification of women at high risk of developing T2DM. These findings may be useful for developing preventive strategies.
Resumo

Objetivo Os objetivos do estudo foram avaliar o estado glicêmico de mulheres com história de diabetes mellitus gestacional (DMG) após o parto e identificar fatores associados ao desenvolvimento de diabetes mellitus tipo 2 (DM2), glicemia de jejum alterada (GJA) e tolerância diminuída à glicose (TDG).

Métodos Coorte retrospectiva de 279 mulheres com DMG reavaliadas com um teste oral de tolerância à glicose (TOTG) após a gestação. Foram analisados fatores prognósticos da gestação índice e fatores de risco para o futuro desenvolvimento de pré-diabetes (GJA ou TDG) e DM2. Resultados: Diagnosticou-se DM2 em 34 pacientes (12,2%), GJA em 58 (20,8%) e TDG em 35 (12,5%). Mulheres que evoluíram para DM2 apresentaram maior frequência de história familiar de DM2, índice de massa corporal (IMC) pré-gestacional mais elevado, menor idade gestacional, níveis superiores de glicemia de jejum e 2 horas após glicose no TOTG ao diagnóstico do DMG, hemoglobina glicada mais elevada, e uso mais frequente de insulina na gestação. História paterna de DM2 (odds ratio [OR] = 5,67; intervalo de confiança de 95% [IC95%] = 1,64–19,59; p = 0,006), glicemia de jejum do primeiro trimestre (OR = 1,07; IC95% = 1,03–1,11; p = 0,001) e o uso de insulina na gestação (OR = 15,92; IC95% = 5,54–45,71; p < 0,001) foram fatores de risco independentes para o desenvolvimento de DM2.

Conclusão Houve elevada incidência de alterações no metabolismo da glicose em mulheres com DMG prévio. História familiar de DM2, IMC pré-gestacional elevado, DMG diagnosticado mais precocemente na gestação, com glicemias mais elevadas e necessidade de insulina, foram importantes fatores de risco associados à identificação precoce de mulheres com alto risco de desenvolvimento de DM2. Este conhecimento pode ser útil para o desenvolvimento de estratégias de prevenção.

Descritores
► diabetes gestacional
► reavaliação pós-parto
► diabetes tipo 2
► teste oral de tolerância à glicose
► fatores de risco

Introduction

Gestational diabetes mellitus (GDM) is historically defined as “any degree of glucose intolerance with onset or first recognition during pregnancy”, and may or may not persist after labor.1 This concept had limitations, considering the inclusion of pregnant women with type 2 diabetes mellitus (T2DM) not previously diagnosed. Thus, it was modified after the study Hyperglycemia and Adverse Pregnancy Outcome (HAPO), which evaluated more than 25,000 pregnant women and intended to find the cutoff point of the maternal plasma glucose associated to the increase of adverse perinatal events.2 The diagnostic patterns for GDM were revised, and the recommendation according to the International Association of Diabetes and Pregnancy Study Groups (IADPSG) since 2010 is that pregnant women who fit the diagnosis of T2DM at the first prenatal appointment be diagnosed as having overt diabetes. New threshold values (cutoff points) to diagnose GDM were adopted, defined as the following values on the oral glucose tolerance test (OGTT) with 75 g of glucose: fasting plasma glucose ≥ 92 mg/dL, after 1 hour ≥ 180 mg/dL and/or after 2 hours ≥ 153 mg/dL; a single abnormal value is enough to diagnose GDM.3,4

The traditionally defined prevalence of GDM was of ~7% of pregnancies (varying from 1 to 14%, depending on the studied population and the diagnostic criteria that were used), and was associated with adverse outcomes, both maternal and fetal.4 After the alterations in the diagnostic criteria, the global prevalence of gestational hyperglycemia increased and was estimated at ~17%, with some regional variations.5,6 The study of Trujillo et al7 applied such parameters to a cohort of more than 5,000 pregnant women of the Brazilian Gestational Diabetes Study, conducted between 1991 and 1995, finding an estimated prevalence of 18% of GDM.

Women who had pregnancies complicated by GDM are at an increased risk of developing T2DM in the postpartum period when compared with those with normal plasma glucose levels during pregnancy.8 A meta-analysis evaluated 28 studies including women with previous GDM, with follow-up ranging between 6 weeks and 28 years after the end of pregnancy, and showed rates of T2DM between 2.6 and 70%, depending on ethnicity, diagnostic criteria, and the follow-up period.9

Women with history of GDM are recommended for re-evaluation regarding the persistence or not of abnormal glucose tolerance within 6 to 12 weeks after labor, following the same diagnostic criteria of the OGTT used outside pregnancy, or with the fasting plasma glucose, but the OGTT is the most sensitive test. If the tests show a normal result, the reevaluation could be done every 3 years. Patients presenting impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) must be reevaluated annually.10
Some studies have already shown that the establishment of T2DM may be postponed or avoided in high-risk groups through changes in lifestyle or medication use. Therefore, the identification of possible characteristics associated with the development of T2DM in women with previous GDM could contribute to the stratification of risk, aiming at prevention programs.

The objective of the study was to reevaluate the glycemic status in women with history of GDM and to identify associations among the pre-pregnancy and pregnancy characteristics and the progression to different glycemic outcomes: T2DM, IFG, and IGT.

Methods

A retrospective cohort of outpatients was followed up at the Prenatal Diabetes Clinic of the Endocrinology Service of Hospital de Clínicas, Universidade Federal do Paraná (HC-UFRP), a tertiary care reference hospital for high-risk pregnancies. Those women presented altered plasma glucose levels during pregnancy, with or without risk factors identified for GDM, and no previous diagnosis of diabetes mellitus (DM). Women who returned to the clinic for postnatal evaluation from 6 to 12 weeks after labor, as advised during prenatal care, were included in the study. Exclusion criteria were the following: diagnosis of type 1 diabetes mellitus (T1DM) or T2DM, according to the criteria of prompt increase of fasting glucose in the first weeks of pregnancy; and/or not having the postpartum OGTT. The study was approved by the HC-UFRP Human Research Ethics Committee.

All records (including standard forms filled by the Endocrinology and Obstetrics team) of patients with GDM followed by the Prenatal Diabetes Clinic of the HC-UFRP Endocrinology and Obstetrics Service between November 2001 and March 2013 were analyzed. The patients who had performed at least one OGTT during the postpartum follow-up care (or who had a fasting plasma glucose compatible with the diagnosis of T2DM) were included in the study. Patients with more than one OGTT during follow-up had the last test performed used for analysis.

Data were collected from the forms filled out at every appointment, the patient’s records, and the Hospital Information System, and through active search by telephone contact with patients who did not return after labor for the OGTT.

The diagnosis of GDM followed the recommendations of the 2nd Meeting of the Diabetes and Pregnancy Task Force until 2011: after positive screening (fasting plasma glucose ≥ 85 mg/dL), 75-g OGTT was performed, and GDM was diagnosed if fasting plasma glucose was ≥ 110 mg/dL and/or 2-hour postprandial plasma glucose after 75-g glucose overload was ≥ 140 mg/dL. After the release of the International Association of Diabetes and Pregnancy Study Groups (IADPSG) guidelines and their inclusion in the recommendations by the American Diabetes Association (ADA), GDM was diagnosed when fasting plasma glucose was ≥ 92 mg/dL at any gestational age, or by using the 75-g OGTT, GDM being diagnosed when at least one of the following was found: fasting plasma glucose ≥ 92 mg/dL; 1 hour plasma glucose ≥ 180 mg/dL; and/or 2-hour plasma glucose ≥ 153 mg/dL.

During the prenatal care appointments, a standard form was filled out with questions about the current and previous medical history of each patient with GDM: age of the patient at diagnosis of GDM; informed pre-pregnancy weight, pre-pregnancy and at GDM diagnosis height and body mass index (BMI), calculated by the equation: weight (kg)/height (m²); family history of T2DM; history of GDM in previous pregnancies; hypertension history or history of hypertensive disorders of pregnancy; gestational age at the beginning of GDM care; fasting plasma glucose values at the first trimester of pregnancy; OGTT glucose values and mean hemoglobin A1c (A1c) in the index pregnancy; the need for insulin treatment (or metformin) during pregnancy; and weight gain until the end of pregnancy (considered excessive or not). Throughout the follow-up period, physical tests were performed for weight, blood pressure and obstetric parameters evaluation. The recommendations of the Institute of Medicine were used to classify the weight gain during pregnancy as insufficient, adequate or excessive, according to the pre-pregnancy body mass index (BMI). Pregnant women with BMI ≤ 18.5 kg/m² should gain between 12.5 and 18 kg; the ones with BMI from 18.5 to 24.9 kg/m², between 11.5 and 16 kg; overweight women (BMI from 25 to 29.9 kg/m²), between 7 and 11.5 kg; and obese women (BMI ≥ 30kg/m²), between 5 to 9 kg.

Patients were advised to follow a dietary treatment. Glucose control was considered good if fasting plasma glucose was < 95 mg/dL, 1 hour postprandial < 140 mg/dL, and 2-hour postprandial < 120 mg/dL. When one or more values of plasma glucose were beyond these therapeutic targets after 2 weeks of lifestyle modification, or when the ultrasonographic evaluation showed signs of excessive fetal growth, pharmacological treatment was indicated.

 Analyzed Results

First, we made a comparison between the group of patients who returned for postpartum reevaluation of glucose tolerance status and the group who did not return and who was, therefore, excluded from the next analysis of subgroups, to ensure we had similar samples. Thus, we were able to verify if the patients who returned for the reevaluation had any special risk factor that could lead to a bias in the analysis, overestimating or underestimating the results, thus limiting or jeopardizing our conclusions.

Patients who returned after labor for reevaluation of glucose tolerance status were divided into four subgroups: T2DM, IFG, IGT, and normal glucose tolerance (NGT). Type 2 diabetes mellitus was diagnosed when fasting plasma glucose was ≥ 126 mg/dL and/or 2-hour after 75-g plasma glucose ≥ 200 mg/dL; IFG, when fasting plasma glucose was ≥ 100 mg/dL and < 126 mg/dL and 2-hour after 75-g normal glucose (< 140 mg/dL); and IGT, when glucose values 2-hour after 75-g glucose were ≥ 140 mg/dL and < 200 mg/dL and fasting plasma glucose was < 126 mg/dL."

Laboratory Tests

Plasma glucose was measured by the hexokinase method, and the hemoglobin A1c by high performance liquid chromatography (HPLC).
**Statistical Analysis**

Pre-gestational and gestational characteristics associated with each clinical outcome were expressed as mean and standard deviation for quantitative variables, and as absolute and relative frequency (percentage) in case of categorical variables. For the numeric variable “time elapsed from the first appointment at the GDM care clinic until the performance of OGTT postpartum”, besides the mean and standard deviation, there were also nominated minimum, maximum, and median values in the corresponding table.

To compare the groups of patients included (who returned for postpartum reevaluation of glucose tolerance status) and the ones excluded from the study (patients who did not return), the Student t-test was used for the quantitative variables, and the Fisher’s exact test or the Chi-square test for categorical variables.

For patients who performed at least one OGTT in the postpartum period and were divided into the subgroups T2DM, IFG, IGT and NGT, the statistical analysis was performed as follows: in the univariate analysis, the groups were compared with analysis of variance (ANOVA) in case of numeric variables with normal distribution, or with the Kruskal-Wallis test for non-parametric variables. For categorical variables, the Chi-square test was used for comparison. In a multivariate analysis with binary logistic regression, only the most important variables to determine the risk of the studied disease. Values of \( p < 0.05 \) showed statistical relevance. The analyses were performed with the statistical software Minitab, version 16.1 (Champaign, IL, USA).

**Results**

From a total of 1,518 pregnancies diagnosed with GDM followed up in our service from November 2001 to March 2013, 279 patients presented some postpartum OGTT (18.4%). From these 279 women who were included in the subgroup analysis, 51 (18.3%) were diagnosed with the new GDM criteria of the IADPSG/ADA.3,4

- Table 1 shows the baseline characteristics of the patients who returned (\( n = 279 \)) and the ones who did not return for the postpartum reevaluation (\( n = 1,239 \)). The only statistically different characteristic between these groups was the gestational age at the diagnosis of GDM, which was lower in patients included in our study (30.7 weeks versus 31.7 weeks; \( p = 0.002 \)).

Among the 279 patients reevaluated in the postpartum period, 127 (45.5%) showed some rate of abnormal glucose tolerance: 34 (12.2%) were diagnosed with T2DM; 93 (33.3%) were considered pre-diabetic (IFG and/or IGT); 58 (20.8%) showed isolated IFG, and 35 (12.5%) showed IGT; and 152 women (54.5%) sustained NGT (Fig. 1).

Concerning family history, women whose mothers presented T2DM had higher chances of developing T2DM in the

---

**Table 1** Baseline characteristics of patients who returned at postpartum for reevaluation of the glycemic status and the patients who did not return

<table>
<thead>
<tr>
<th>Baseline characteristics</th>
<th>Postpartum reevaluation (( n = 279 ))</th>
<th>No postpartum reevaluation (( n = 1,239 ))</th>
<th>( p )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at GDM diagnosis (years)</td>
<td>32.1 ± 6.1</td>
<td>31.8 ± 6.4</td>
<td>0.530*</td>
</tr>
<tr>
<td>Father with T2DM</td>
<td>40 (14.3)</td>
<td>175 (14.1)</td>
<td>0.927**</td>
</tr>
<tr>
<td>Mother with T2DM</td>
<td>85 (30.5)</td>
<td>333 (26.9)</td>
<td>0.225**</td>
</tr>
<tr>
<td>Pre-gestational weight (kg)</td>
<td>70.6 ± 14.7</td>
<td>71.7 ± 16.6</td>
<td>0.288*</td>
</tr>
<tr>
<td>BMI 1 (kg/m²)</td>
<td>27.9 ± 5.7</td>
<td>28.2 ± 6.1</td>
<td>0.596*</td>
</tr>
<tr>
<td>History of chronic hypertension or hypertensive pregnancy disorders</td>
<td>75 (26.9)</td>
<td>315 (25.4)</td>
<td>0.615**</td>
</tr>
<tr>
<td>Gestational age at diagnosis of index pregnancy with GDM (weeks)</td>
<td>30.7 ± 4.7</td>
<td>31.7 ± 4.7</td>
<td>0.002*</td>
</tr>
<tr>
<td>First trimester fasting plasma glucose (mg/dL)</td>
<td>89.1 ± 12.5</td>
<td>88.1 ± 12.1</td>
<td>0.240*</td>
</tr>
<tr>
<td>Fasting plasma glucose – OGTT (mg/dL)</td>
<td>95.7 ± 19.3</td>
<td>95.3 ± 18.2</td>
<td>0.744*</td>
</tr>
<tr>
<td>75-g-2-hour glucose – OGTT (mg/dL)</td>
<td>167.8 ± 31.3</td>
<td>168.0 ± 31.1</td>
<td>0.906*</td>
</tr>
<tr>
<td>Gestational weight at diagnosis of GDM (kg)</td>
<td>79.3 ± 14.8</td>
<td>80.1 ± 16.3</td>
<td>0.475*</td>
</tr>
<tr>
<td>BMI 2 (kg/m²)</td>
<td>31.4 ± 5.9</td>
<td>31.4 ± 5.9</td>
<td>0.933*</td>
</tr>
<tr>
<td>Insulin/metformin treatment in pregnancy</td>
<td>84/2 (30.1/0.7)</td>
<td>345/8 (27.8/0.6)</td>
<td>0.739†</td>
</tr>
</tbody>
</table>

Abbreviations: BMI 1, body mass index, with the pre-gestational weight; BMI 2, body mass index, with the gestational weight at GDM diagnosis; GDM, gestational diabetes mellitus; OGTT, oral glucose tolerance test; T2DM, type 2 diabetes mellitus.

Notes: Results are expressed as: mean ± standard deviation or n (%).

*Student’s t-test, \( p < 0.05 \); values are expressed as mean ± standard deviation.

**Fisher’s exact test, \( p < 0.05 \); values are expressed as n (%). † Chi-square test, \( p < 0.05 \); values are expressed as n (%).
postpartum period ($p = 0.009$), while women whose fathers had a history of T2DM showed only a slight tendency to develop T2DM, but it was statistically non-significant in the univariate analysis ($p = 0.073$) (–Table 2).

Pre-gestational weight was higher in women who developed T2DM compared with the ones who maintained NGT (77.4 ± 16.7 versus 69.0 ± 13.5; $p = 0.031$), and pre-pregnancy BMI was also higher (30.6 ± 6.0 versus 27.4 ± 5.5; $p = 0.028$) (–Table 2).

Women who progressed to T2DM in the postpartum period had the diagnosis of GDM at 28.3 ± 5.7 weeks of pregnancy, whereas the NGT women at 31.1 ± 4.3 weeks, showing an early diagnosis of GDM for patients with later T2DM ($p = 0.019$). Comparing the fasting plasma glucose of the first trimester of pregnancy among the four groups, those who progressed to T2DM had higher glucose values ($p < 0.001$). Plasma glucose obtained by the OGTT during pregnancy showed difference between the groups, with higher mean levels of fasting plasma glucose and 2-hour plasma glucose in women who progressed to T2DM. The mean hemoglobin A1c test during pregnancy was also higher in women with T2DM ($p < 0.001$) (–Table 2).

Considering the categorical variables, there was only a significant difference regarding insulin need (or need of an additional therapy like metformin) in the gestational period, being more frequent for the patients who developed T2DM in the postpartum period ($p < 0.001$). It is important to stress that only two patients used metformin during pregnancy, whereas the NGT women at 31.1 ± 4.3 weeks showed a 1.9-fold increased risk of developing any abnormal glucose tolerance in patients with history of GDM.15

Our study showed that women with a family history of T2DM, higher pre-pregnancy BMI, earlier diagnosis of GDM, higher levels of plasma glucose at the diagnosis of GDM, and the need of insulin are the ones with an increased risk of developing T2DM in the postpartum period.

Regarding the age at GDM diagnosis and the progression to T2DM, many studies have not shown a link between those variables.9,14,17-21 Additionally, we have not found an age difference between women who progressed to T2DM, IFG, or IGT compared with the ones who maintained the NGT.

Early gestational age at the diagnosis of GDM was associated with the progression to T2DM, a finding also described by Bartha et al,22 who reported the early diagnosis of GDM in the first half of pregnancy as a risk factor for the onset of T2DM. Other studies have also shown this association,18,19,23 while some do not corroborate such finding.17,20
# Table 2: Risk factors associated with postpartum glycemic status

<table>
<thead>
<tr>
<th>Glucose tolerance categories</th>
<th>T2DM (n = 34)</th>
<th>IFG (n = 58)</th>
<th>IGT (n = 35)</th>
<th>NGT (n = 152)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age at GDM diagnosis (years)</strong></td>
<td>33.7 ± 5.3</td>
<td>33.0 ± 6.3</td>
<td>31.7 ± 6.1</td>
<td>31.7 ± 6.1</td>
</tr>
<tr>
<td><strong>Father with T2DM</strong></td>
<td>9 (26.5)</td>
<td>5 (8.6)</td>
<td>7 (20.0)</td>
<td>19 (12.5)</td>
</tr>
<tr>
<td><strong>Mother with T2DM</strong></td>
<td>16 (47.1)</td>
<td>17 (29.3)</td>
<td>16 (45.7)</td>
<td>36 (23.7)</td>
</tr>
<tr>
<td><strong>Pre-gestational weight (kg)</strong></td>
<td>77.4 ± 16.7</td>
<td>70.4 ± 15.7</td>
<td>71.3 ± 15.2</td>
<td>69.0 ± 13.5</td>
</tr>
<tr>
<td><strong>BMI (kg/m²)</strong></td>
<td>27.6 ± 5.6</td>
<td>26.9 ± 5.9</td>
<td>27.4 ± 5.5</td>
<td>27.6 ± 5.4</td>
</tr>
<tr>
<td><strong>History of chronic hypertension or hypertensive pregnancy disorders</strong></td>
<td>20 (58.8)</td>
<td>13 (22.4)</td>
<td>13 (37.1)</td>
<td>19 (12.5)</td>
</tr>
<tr>
<td><strong>Previous GDM</strong></td>
<td>9 (26.5)</td>
<td>5 (8.6)</td>
<td>7 (20.0)</td>
<td>19 (12.5)</td>
</tr>
<tr>
<td><strong>Gestational age at diagnosis of index pregnancy (weeks)</strong></td>
<td>28.3 ± 5.7</td>
<td>28.3 ± 5.7</td>
<td>28.3 ± 5.7</td>
<td>28.3 ± 5.7</td>
</tr>
<tr>
<td><strong>First trimester fasting plasma glucose (mg/dL)</strong></td>
<td>98.8 ± 16.5</td>
<td>95.4 ± 12.0</td>
<td>96.9 ± 13.4</td>
<td>96.0 ± 10.1</td>
</tr>
<tr>
<td><strong>Gestational weight at diagnosis of GDM (kg)</strong></td>
<td>85.4 ± 16.6</td>
<td>80.1 ± 15.8</td>
<td>78.6 ± 15.9</td>
<td>77.9 ± 13.3</td>
</tr>
<tr>
<td><strong>BMI 2 (kg/m²)</strong></td>
<td>31.5 ± 6.4</td>
<td>30.6 ± 6.0</td>
<td>30.6 ± 6.0</td>
<td>30.6 ± 6.0</td>
</tr>
<tr>
<td><strong>Excessive weight gain during pregnancy</strong></td>
<td>5 (15.2)</td>
<td>2 (3.4)</td>
<td>2 (5.7)</td>
<td>5 (3.3)</td>
</tr>
<tr>
<td><strong>Insulin treatment start in pregnancy (gestational age – weeks)</strong></td>
<td>29.1 ± 4.2</td>
<td>30.9 ± 5.8</td>
<td>27.5 ± 7.9</td>
<td>26.7 ± 7.9</td>
</tr>
<tr>
<td><strong>Elapsed time from first appointment to postpartum OGTT (months)</strong></td>
<td>22.1 ± 5.9</td>
<td>22.1 ± 5.9</td>
<td>22.1 ± 5.9</td>
<td>22.1 ± 5.9</td>
</tr>
<tr>
<td><strong>Insulin treatment start in pregnancy</strong></td>
<td>27 (79.4)</td>
<td>23 (37.9)</td>
<td>19 (54.3)</td>
<td>29 (19.1)</td>
</tr>
<tr>
<td><strong>Insulin dose in pregnancy (IU)</strong></td>
<td>19.7 ± 14.9</td>
<td>14.3 ± 10.7</td>
<td>16.9 ± 10.5</td>
<td>10.6 ± 8.1</td>
</tr>
<tr>
<td><strong>Elapsed time from first appointment to postpartum OGTT (months)</strong></td>
<td>9.2 ± 13.8</td>
<td>5.9 ± 5.3</td>
<td>16.2 ± 16.8</td>
<td>3.8 ± 3.0</td>
</tr>
</tbody>
</table>

**Abbreviations:** BMI, body mass index; GDM, gestational diabetes mellitus; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; NGT, normal glucose tolerance; OGTT, oral glucose tolerance test; T2DM, type 2 diabetes mellitus.

**Notes:** Results are expressed as mean ± standard deviation; n (%); median (minimum – maximum).

- *p < 0.05; values are expressed as mean ± standard deviation.
- **p < 0.001; values are expressed as median (minimum – maximum). Excessive gestational weight gain was defined according to the 2009 Institute of Medicine guidelines based on body mass index.***
Considering family history of T2DM and the risk of developing T2DM among women with GDM, some authors have not found the link we observed in our study.\textsuperscript{18–20,24} We demonstrated that women who had GDM and whose mothers were diabetic presented higher rates of T2DM postpartum, in the univariate analysis, whereas the paternal history of T2DM showed a 5.67-fold increase risk of future T2DM. Had our sample of patients been larger, we could have possibly found the mother history with T2DM as an independent factor of progression to T2DM, as shown with IGT (OR = 3.15; 95%CI = 1.43–6.97; p = 0.005). Several authors have also confirmed the association between positive family history of T2DM and risk of developing T2DM during the postpartum period.\textsuperscript{25,26} The Brazilian cohort of Weinert et al\textsuperscript{26} found that family history of T2DM was one of the factors associated with the prevalence of hyperglycemia in the postpartum period.

Several studies have associated the pre-pregnancy BMI of women with GDM with the risk of T2DM,\textsuperscript{9,17,18,24,27} but others have not corroborated that connection.\textsuperscript{28} Kwak et al\textsuperscript{29} showed that obesity was a risk factor for the progression to T2DM. Another study has related central obesity at the moment of GDM diagnosis to an increased risk for glucose metabolism alterations in the postpartum period.\textsuperscript{15} In our analysis, weight and pre-pregnancy BMI were associated with the development of T2DM. We have not identified a connection between weight gain in pregnancy and T2DM, which has also been described in other studies.\textsuperscript{24,30}

Kim et al\textsuperscript{9} pointed out the association between the high level of fasting plasma glucose during pregnancy in women with GDM and the progression to T2DM. Our study verified similar results, since the patients who had higher fasting plasma glucose in the beginning of pregnancy showed an increased rate of postpartum abnormal glucose tolerance, standing out as a risk factor, apart from the progression of all of the evaluated glycemic outcomes, which could reflect decreased pancreatic reserve before pregnancy or aspects such as the aggravation or setup of obesity during pregnancy. Other studies also linked high levels of fasting plasma glucose in OGTT during pregnancy to a greater frequency of T2DM development in the postpartum period.\textsuperscript{17,23,24,27} Chew et al\textsuperscript{27} observed that the elevated fasting plasma glucose during pregnancy was an independent risk factor for T2DM, for isolated IGT, and for the association of IGT and GDM (p < 0.05). Schaefer-Graf et al\textsuperscript{23} reported a risk of developing T2DM 21-fold higher if the fasting plasma glucose during pregnancy was higher than 121 mg/dL. Therefore, fasting plasma glucose seems to be the most important variable for the establishment of T2DM in the postpartum period,\textsuperscript{23,31} and remains an independent predictor for T2DM in long-term analyses.\textsuperscript{24} However, an Australian study with 5,470 women with GDM did not confirm the association between fasting plasma glucose and the risk of T2DM.\textsuperscript{23} The study verified the rate with glycemic levels 1 hour after glucose in OGTT, but fasting plasma glucose and 2-hour after glucose overload in the OGTT were not associated with the development of T2DM during follow-up, which lasted 2.5 years for 43.8% of the women, and 15 years for 5.1%.

We observed the association between the mean hemoglobin A1c during pregnancy and the postpartum T2DM diagnosis (p < 0.001). Ekelund et al\textsuperscript{25} have shown a 4.8-fold increased risk of T2DM in a 5-year follow-up if hemoglobin A1c was ≥ 5.7% (National Glycohemoglobin Standardization Program) or the equivalent hemoglobin A1c was ≥ 4.7% with the Swedish Mono S method, but the association with fasting plasma glucose levels has been more significant.

We related the insulin need during pregnancy to the progression of abnormal glucose tolerance. Among the patients diagnosed with T2DM in the postpartum period, 79.4% used insulin, while among the ones who maintained NGT, only 18.4% needed insulin treatment. In a multivariate analysis, insulin need was associated with a 15.92-fold increased risk of progressing to T2DM. Insulin treatment during pregnancy has been consistently associated with the development of long-term T2DM, but this finding could simply reflect the degree of fasting hyperglycemia. Some studies have corroborated the connection between the need

<table>
<thead>
<tr>
<th>Risk factors for T2DM</th>
<th>p</th>
<th>OR [95%CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>First trimester fasting plasma glucose (mg/dL)</td>
<td>0.001</td>
<td>1.07 [1.03–1.11]</td>
</tr>
<tr>
<td>Father with T2DM</td>
<td>0.006</td>
<td>5.67 [1.64–19.59]</td>
</tr>
<tr>
<td>Insulin/metformin treatment in pregnancy</td>
<td>&lt; 0.001</td>
<td>15.92 [5.54–45.71]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk factors for IGT</th>
<th>p</th>
<th>OR [95%CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>First-trimester fasting plasma glucose (mg/dL)</td>
<td>0.008</td>
<td>1.04 [1.01–1.08]</td>
</tr>
<tr>
<td>Mother with T2DM</td>
<td>0.005</td>
<td>3.15 [1.43–6.97]</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Risk factors for IFG</th>
<th>p</th>
<th>OR [95%CI]</th>
</tr>
</thead>
<tbody>
<tr>
<td>First trimester fasting plasma glucose (mg/dL)</td>
<td>0.022</td>
<td>1.04 [1.00–1.07]</td>
</tr>
<tr>
<td>Insulin/metformin treatment in pregnancy</td>
<td>0.021</td>
<td>2.29 [1.13–4.64]</td>
</tr>
</tbody>
</table>

Abbreviations: 95%CI, 95% confidence interval; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; OR, odds ratio; T2DM, type 2 diabetes mellitus.

Note: p < 0.05.
for insulin and the risk of T2DM,\textsuperscript{19,20,26,32} while others have not.\textsuperscript{21,24} It should be considered that insulin use during pregnancy for the treatment of GDM depends on local protocols and on the patient’s acceptance; therefore, it is not surprising that such an association is inconsistent in different studied populations.

According to the literature, the frequency of T2DM in women with previous GDM varies between 2.6 and 70%.\textsuperscript{6,9,21} Feig et al\textsuperscript{33} estimated the probability of developing T2DM after GDM in 3.7% over 9 months after delivery, and 18.9% 9 years later. This variation is due to the great diversity of tests, selection bias, and elapsed time in the follow-up especially. In our study, we found an incidence of 12.2% of T2DM, observing an important variation concerning time of follow-up, with a mean of 24.7 \pm 26.9 months between labor and the disease diagnosis.

Patients with GDM in our study are systematically guided and encouraged to return in 6 to 12 weeks after labor and subsequently every 6 months or annually, depending on the results. Nevertheless, the majority did not return for reevaluation, and only 18.4% of them had some postpartum OGTT, which was a limiting factor in our study. The lack of follow-up is also reported by several other authors, with rates of reevaluation fluctuating between 20 and 50.2%.\textsuperscript{33–38} The meta-analysis of Tovar et al\textsuperscript{39} checked that the time elapsed between labor and the reevaluation of the women who had been diagnosed with GDM was greater than recommended in most of the analyzed studies. One of the exceptions is Australia, where there is great focus on tracking T2DM in the postpartum period, with data showing levels of up to 73% of follow-up.\textsuperscript{40} However, when comparing patients who did not return after labor to the ones who returned for reevaluation, we did not observe significant differences in basal characteristics, family history of T2DM, or use of insulin/metformin during pregnancy. The only difference was related to the gestational age at GDM diagnosis, which was earlier in the included patients, a fact that had no correlation with the progression of those patients during pregnancy according to the evaluated parameters.

The lack of follow-up was possibly due to the difficulty in collecting patients after labor, probably because the first laboratorial reevaluation, when the bond between the patient and the study was established, matched the period of adaptation of the woman to the newborn and its multiple demands. Another hypothesis, which could have the same reason, is that the reevaluation of the glucose tolerance status was performed in health care centers closer to the patient’s home.

Another limitation in our study was related to the criteria used for the diagnosis of GDM, which varied over the follow-up time. It is important to note that there is still no consensus regarding the ideal criteria for the diagnosis. We followed, until 2011, the criteria then current in our country, those of the 2nd Meeting of the Diabetes and Pregnancy Task Force, and thereafter we started to use the recommendations of ADA,\textsuperscript{40} now the most accepted criteria. That division may have set a limitation to the study. Previously, the criteria recommended by the World Health Organization (WHO) had been followed for the diagnosis of GDM, the same cutoff used when not pregnant (fasting plasma glucose \( \geq 126 \) mg/dL or plasma glucose 2-hour after overload with 75-g glucose \( \geq 140 \) mg/dL).\textsuperscript{41} However, in our study we chose to use the criteria of the 2nd Meeting of the Diabetes and Pregnancy Task Force, which included an intermediary category between normal and diabetes, the impaired fasting glucose (glucose between 110 and 126 mg/dL) to diagnose GDM. This could have been considered a possible bias of the sample used in our study, that is, a greater number of patients being diagnosed with the disease at that time. However, we do not consider that as a limitation affecting our results, since currently the cutoff point of fasting plasma glucose is even lower, and the criteria for the GDM diagnosis have changed considerably over time and are still quite controversial among numerous institutions and experts who study diabetes and pregnancy.

Lastly, we showed that some characteristics present during pregnancy may help identify women most likely to develop abnormal glucose tolerance in the postpartum period. Those characteristics could be used to assist the adoption of prevention strategies based on individual risk in our population, focusing on patients with a higher risk, in a situation of limited financial resources. Several studies have shown that individuals with a high risk for the development of T2DM (IFG, IGT, patients with history of GDM) could significantly decrease the incidence of T2DM through some specific interventions.\textsuperscript{11,12,42} Those measures include programs of intensive lifestyle changes, such as diet and regular physical activity, and the use of medications such as metformin, α-glucosidase inhibitors, orlistat, and thiazolidinedione, all of which have been shown to decrease the incidence of T2DM. Regarding the use of medication in patients with a history of GDM, the use of metformin was shown to decrease the risk of T2DM in ~ 50% of patients in the study of Ratner et al,\textsuperscript{11} from the Diabetes Prevention Program (DPP). Aroda et al\textsuperscript{12} recently published a 10-year follow-up study of DPP women. Among the women with a history of GDM, the group that had changed their lifestyle intensively showed a decrease in incidence of T2DM in 35%, and the group using metformin had a 40% reduction, while those in the placebo group showed a 48% higher risk of developing the disease.\textsuperscript{12} Regarding the randomized women in this study with no previous history of GDM, those who participated in the lifestyle changes lowered the risk for T2DM, while those randomized for the use of metformin did not show a decline in the incidence of T2DM. These data suggest that metformin may be more effective in women with previous GDM than in women without this history, suggesting that it might be an interesting medication for use in this population.

Strategies to increase the return index for the glucose status reevaluation in the postpartum, and eventually to prevent T2DM, should include the following: guidance during prenatal care and immediately at postpartum, showing the importance of the reevaluation, and even contact with the patients (through phone calls, for example) if they do not attend the appointment.
Health policy must be encouraged to make these women aware and to assure their return after labor for adequate reevaluation. Some characteristics present during pregnancy may help identify the women most likely to develop abnormal glucose tolerance in the future and, therefore, assist in the adoption of prevention strategies based on the individual risk.

References

34. Lawrence JM, Black MH, Hsu JW, Chen W, Sacks DA. Prevalence and timing of postpartum glucose testing and sustained glucose


